United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $235.35, for a total value of $847,260.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company's stock, valued at approximately $30,595.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Price Performance
Shares of NASDAQ UTHR opened at $255.14 on Thursday. United Therapeutics Co. has a 1-year low of $204.44 and a 1-year high of $261.54. The business has a 50-day moving average of $234.62 and a 200-day moving average of $228.81. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The company has a market capitalization of $11.32 billion, a price-to-earnings ratio of 12.86 and a beta of 0.54.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business had revenue of $614.70 million for the quarter, compared to analysts' expectations of $575.01 million. During the same quarter in the previous year, the firm posted $2.67 earnings per share. The company's revenue was up 25.1% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings | Ad
Don’t panic — you haven’t missed the boat on AI.
In fact, it has barely launched.
Sure, the early stages of this boom were big …
But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.
Several institutional investors have recently modified their holdings of the business. Access Investment Management LLC lifted its stake in shares of United Therapeutics by 137.2% in the first quarter. Access Investment Management LLC now owns 7,210 shares of the biotechnology company's stock worth $1,656,000 after acquiring an additional 4,170 shares in the last quarter. GLOBALT Investments LLC GA acquired a new stake in United Therapeutics during the first quarter valued at approximately $207,000. Capstone Investment Advisors LLC raised its stake in United Therapeutics by 90.9% during the first quarter. Capstone Investment Advisors LLC now owns 5,062 shares of the biotechnology company's stock valued at $1,163,000 after buying an additional 2,410 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in United Therapeutics by 2.3% during the first quarter. Janney Montgomery Scott LLC now owns 8,960 shares of the biotechnology company's stock valued at $2,058,000 after buying an additional 201 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in United Therapeutics during the first quarter valued at approximately $2,871,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on UTHR. HC Wainwright reissued a "buy" rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. The Goldman Sachs Group raised United Therapeutics from a "sell" rating to a "neutral" rating and boosted their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs reissued an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, April 11th. Finally, Wells Fargo & Company boosted their price target on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a research report on Thursday, March 7th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $294.25.
View Our Latest Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
